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Abstract: Captopril (CAP) was the first angiotensin I-converting enzyme (ACE) inhibitor to be 
developed and is widely used in hypertension treatment. On the other hand, cyclodextrins (CDs) 
are cyclic oligosaccharides whose cone-shaped cavity allows formation of noncovalent inclusion 
complexes with appropriately sized guest molecules, thus modifying guest physical, chemical, 
and biological properties. Herein, the physicochemical characterization and in vivo ACE inhi-
bition evaluation of seven CAP/CD complexes are reported. The inclusion complexes were 
prepared by spray-drying, freeze-drying, kneading, or lyophilization methods and   characterized 
by nuclear magnetic resonance, Fourier-transformed infrared spectroscopy, X-ray diffraction, 
differential scanning calorimetry, and scanning electron microscopy   techniques. In vivo assays 
compared CAP and CAP/CD complex administration (0.5 mg kg−1 or 0.09 mg kg−1, n = 4–7) 
to evaluate the ACE inhibition by continuous infusion of angiotensin I (30 ng 50 µL−1 min−1) 
in conscious Wistar rats. The physicochemical analysis demonstrated complete amorphization 
and complexation between CAP and CDs, indicating the substitution of water molecules inside 
the CD cavity with CAP. During the infusion of angiotensin I, the administration of all CAP/
CD complexes induced a reduction in mean arterial pressure similar to that observed upon 
CAP administration. The nanoparticles obtained by the kneading method (CAP/α-CD:KM) 
showed a potent and long-lasting inhibitory activity (∼22 hours) on the angiotensin I pressor 
effect. The results suggest that the inclusion complex of CAP and α-CD can function as a novel 
antihypertensive formulation that may improve therapeutic use of CAP by reducing its oral 
dose administration to once per day, thus providing better quality of life for almost 25% of the 
world’s population who suffer from hypertension.
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Introduction
Captopril (CAP) (Figure 1) is an angiotensin I-converting enzyme inhibitor1 that has 
been widely used for the treatment of hypertension and congestive heart failure. This 
drug acts orally and the dosage used for the treatment of these heart diseases ranges 
from 50 mg to 150 mg per day. With a single oral dose its maximum hemodynamic 
effect is observed after 45–90 minutes.1 The drug is also freely water soluble, has 
an elimination half-life of 1.7 hours, and is stable at pH 1.2. As the pH increases, 
CAP becomes unstable and undergoes degradation.2,3 CAP has been a drug of 
choice in hypertension management; however, its antihypertensive action is effec-
tive for 6–8 hours, which is why three to four CAP administrations are required for 
successful medication.   Therefore, development of a controlled delivery system for 
CAP would bring many advantages for hypertension patients, who compose almost International Journal of Nanomedicine 2011:6
Figure 1 captopril (cAP) ((2s)-1-[(2s)-2-methyl-3-sulfanylpropanoyl]-pyrrolidine-
2-carboxylic acid) (left) and α- and β-cyclodextrins (cD) (middle and right) with 
indication  of  the  captopril  and  cyclodextrin  hydrogens.  The  cAP  and  α-cD 
hydrogens  are  colored  purple,  red,  or  green,  due  to  observed  interactions  as 
indicated in nuclear magnetic resonance section.
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25% of the world’s population.4,5 Development of oral 
  controlled-release formulations for CAP is very difficult 
due to both in vivo and in vitro instability. The drug also 
undergoes dose dumping and burst phenomena (being freely 
water soluble) when   formulated as controlled- or sustained-
release formulations.6
Natural and semisynthetic cyclodextrins (CDs) have been 
extensively studied as host molecules, as they improve certain 
properties of drugs, such as solubility, stability, and bioavail-
ability.7 These saccharides are suitable drug delivery systems 
because of their ability to greatly modify physicochemical 
properties and/or biological properties of guest molecules 
through labile interactions in the host/guest inclusion com-
plexes formed. As was recently divulged by some of the 
authors of the present work, auraptene and 4’-geranylloxy-
ferulic acid in inclusion complexes with β-CD exhibit very 
effective results in inhibiting colon cancer.8 The inclusion of 
the active principles in the cage of β-CD9,10 protected drugs 
from absorption in the stomach and the upper portion of the 
lower intestine and enabled the degradation of the saccharide 
portion in the large bowel by intestinal microflora, thereby 
ensuring specific drug delivery with the maximum drug 
bioavailability. Although investigation into drug inclusion 
is one of the most extensively researched fields, and compl-
exation and self-assembly of CDs and lipophilic drugs has 
been investigated for years,11–13 interactions between CDs and 
hydrophilic drugs have scarcely been reported.14–16 Such an 
interaction could result in a retarding effect of the associated 
hydrophilic drug. Therefore, one of the goals of the present 
work was to investigate whether a hydrophilic drug such as 
CAP could form associations or even complexes with CDs 
so as to obtain a potential antihypertensive formulation that 
may improve the therapeutic use of CAP.
Ikeda et al17 reported on controlled CAP release by com-
bining hydrophilic and hydrophobic CDs and derivatives in 
aqueous solutions in self-assembled complexes. Their results 
suggested that a combination of HP- and TB-β-CD with CAP 
could control the CAP release by adjusting the molar ratio 
between the inclusion complex components. In an article 
published in 2002, Ikeda et al18 also showed inclusion com-
plex formation between α-, β-, and HP-β-CDs as hosts, and 
CAP in aqueous solutions, analyzed principally by 1H and 13C 
nuclear magnetic resonance (NMR) spectroscopy.18
Herein, solid inclusion complex formation between CAP 
and three CDs (α-, β-, and HP-β-CDs) is reported, and to 
assure that complexation between hydrophilic molecules and 
CDs is possible, four types of nanoparticles were obtained: 
kneaded, lyophilized, freeze-dried, and spray-dried. Fifteen 
inclusion complexes were then analyzed by applying classical 
methods, such as NMR, Fourier-transformed infrared (FTIR), 
differential scanning calorimetry (DSC), X-ray diffraction 
(XRD), and scanning electron microscopy (SEM).
Because a focus of our work was the sustained release of 
CAP, in vivo tests were executed with seven of the formula-
tions and compared with CAP. The increase of the duration 
and magnitude of hypotensor CAP effects in the control 
of blood pressure in spontaneously hypertensive rats19 was 
observed. Therefore, nanoparticles of CAP and CD represent 
possible sustained-release devices that increase the duration 
and magnitude of CAP antihypertension effects.
Experimental section
reagents
CAP was purchased from Grupo Castro Marques (União 
Química Farmacêutica/Biolab Sanus, Lote 0500012197, 
Sao Paulo, Brazil) and from FURP (Lote RR379435/1, Sao 
Paulo, Brazil). α-CD and β-CD were purchased from ISP 
Technologies, Inc (Waterford, MI), and 2-hydroxipropyl-
β-CD (Kleptose/HP-β-CD) was purchased from Roquette 
(Lestrem, France).
Inclusion compound preparation 
methods
All inclusion compounds were prepared by kneading method 
(KM), vacuum evaporation (VE), freeze-drying (FD), or 
spray-drying (SD) using 1:1 molar ratios between CAP and 
the corresponding CD. Physical mixtures (PM) were prepared 
by homogeneous blending of weighted CAP and CDs (α-CD, 
β-CD, and HP-β-CD) in a mortar.
Kneading method (KM)
CAP (217 mg) and α-CD (972 mg), β-CD (1135 mg), or 
HP-β-CD (1413 mg), in molar ratios of 1:1, were accurately 
weighed and transferred to a mortar, triturated with a small International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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amount of water, and kneaded thoroughly for approximately 
50 minutes. During this process, an appropriate volume of 
water was added in order to maintain a suitable consistency 
and to avoid CAP degradation.
Vacuum evaporation (Ve)
CAP–ethanol solutions of 500 mg 280 mL−1 were mixed 
with β-CD aqueous solutions (2599 mg 420 mL−1). The 
solutions were mixed for 20 minutes by sonication until clear 
solutions were obtained. Then, the ethanol was evaporated 
under vacuum for 40 minutes and the products were dried 
at 37°C for 48 hours. The two other CAP/CD formulations 
were obtained by the same protocol.
Freeze-drying (FD)
An appropriate amount of CD was dissolved in water. After 
that, CAP was added to this solution under stirring, with 1:1 
stoichiometry. The suspension was stirred for 24–48 hours. 
The resultant clear solutions were frozen by immersion in an 
ethanol bath at –50°C (Freezone model 79490; Shell Freezer, 
  Labconco, Kansas City, MO) and then the frozen solutions 
were lyophilized in a freeze-dryer (ModulyoD-115; Thermo 
Fisher Scientific, Inc, Waltham, MA) for 72 hours.
spray-drying (sD)
For this purpose, the hydroalcoholic solutions were 
  prepared and spray-dried. The suspensions of CAP and 
α-CD (972 mg), β-CD (1135 mg), or HP-β-CD (1413 mg) 
were prepared in a molar ratio of 1:1 and in ethanol:water 
(1:3, v/v). These were mixed and stirred for 24–48 hours. 
The pH values of the solutions were adjusted during this 
process to avoid possible CAP degradation. Solutions were 
subsequently spray-dried in a mini Spray Dryer (B-290; 
Büchi, Flawil, Switzerland) with a two-component nozzle 
and concurrent flow. The drying conditions were as fol-
lows: flow rate, 10 mL s−1; inlet temperature of the drying 
chamber ∼130°C; outlet temperature, 69°C; and airflow rate, 
400 L h−1. The residual water content of each spray-dried 
product was determined by loss of weight, and each analysis 
was repeated three times.
Fifteen samples were obtained (each CD with CAP in five 
different nanoparticle preparations): 1) CAP/β-CD:PM; 2) 
CAP/β-CD:KM; 3) CAP/β-CD:VE; 4) CAP/β-CD:FD; 5) CAP/
β-CD:SD; 6) CAP/α-CD:PM; 7) CAP/α-CD:KM; 8) CAP/α-
CD:VE; 9) CAP/α-CD:FD; 10) CAP/α-CD:SD; 11) CAP/
HP-β-CD:PM; 12) CAP/HP-β-CD:KM; 13) CAP/HP-β-CD:VE; 
14) CAP/HP-β-CD:FD; and 15) CAP/HP-β-CD:SD. Seven of 
these samples were investigated more thoroughly.
NMr spectroscopy
The CAP/CD nanoparticle samples were prepared in D2O 
(99.9%) or in DMSO-d6, purchased from Cambridge 
Isotope Laboratories (Andover, MA), at concentrations of 
approximately 15 mg mL−1. All experiments were performed 
at 298 K in an INOVA-500 spectrometer (Varian, Palo 
Alto, CA). The 1H NMR experiments (D2O samples) were 
acquired with 32 k data points applying a 90° excitation 
pulse with duration of 3.15 µs, spectral width of 4.5 kHz, 
acquisition time of 4 seconds, and relaxation delay of 1 sec-
ond, using a 5 mm triple resonance probe. The diffusion 
ordered spectroscopy (DOSY) experiments were carried out 
through the gradient compensated stimulated echo spin lock 
with convection compensation (DgcsteSL_cc) high-reso-
lution DOSY sequence. Twenty-five different amplitudes 
of the gradient pulses ranging from 6.85 × 10−4 T cm−1 to 
4.22 × 10−3 T cm−1 were applied, achieving an approximately 
90%–95% decrease in the resonance intensity with the 
highest gradient amplitudes. The baselines of all spectra 
were corrected and then the DOSY macro program (Varian) 
was used, involving the determination of the peak heights 
of all signals above a pre-established threshold. The curves 
of each peak were fitted with corresponding exponential 
decay. The DOSY data represent pseudo two-dimensional 
spectra having 1H-NMR chemical shifts along one axis and 
the calculated diffusion coefficients (10−10 m 2 s −1) along 
the other. In the rotating-frame Overhauser enhancement 
spectroscopy (ROESY) experiments, selective (180°) and 
nonselective (90°) pulses with a mixing time of 400 ms and 
300 ms during the spin lock were applied, and the relaxation 
delay was 1.5 seconds. A modulator generated the selective 
pulses and automatically attenuated the power and duration 
of the pulse. 13C NMR and heteronuclear single-quantum 
correlation (HSQC) (DMSO-d6 samples) were carried in 
5 mm broadband or triple resonance probes, respectively. 
13C NMR experiments were acquired with 32 k data 
points, spectral width of 3.0 kHz, and relaxation delays of 
1.5 seconds at 125.709 MHz. The {13C-1H} HSQC spectra 
were obtained with data size and spectral widths of 128 
(t1) × 1024 (t2) and 22800 Hz (ω1, 13C) × 4000 Hz (ω2, 
1H), respectively, and relaxation delays of 1.5 seconds.
FTIr spectroscopy
Samples of the solid dispersions and physical mixtures of 
CAP and α-, β-, and HP-β-CD in molar ratios of 1:1 were 
mixed with KBr and pressed to small tablets mounted in the 
infrared beam (MB 100 FTIR spectrometer; ABB Bomem, 
Inc, Zurich, Switzerland).International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Dsc
Measurements of the pure materials (CAP and CD) and the 
binary systems were carried out using a DSC-STAR system 
(Mettler Toledo Inc, Columbus, OH). The thermal behavior 
was studied by heating the samples in a sealed aluminum pan 
from 25°C to 600°C at a rate of 10°C min−1 under a nitrogen 
flow of 40–50 mL min−1.
XrD studies
The powder XRD patterns of the samples were recorded using 
a Siemens D 5000-XRD (Siemens Electronical Equipment, 
Toronto, ON) under the following conditions: target, Cu; 
filter, Ni; voltage, 40 kV; current, 30 mA; scanning speed 
2°C min−1; chart speed, 40 mm min−1; and count range, 1000 
counts s−1. The detector was a proportional counter with 1.7 
kV detector.
seM studies
The morphological features of CAP, α- and β-CDs, and 
the CAP/CD systems (physical mixture, kneaded, vacuum-
evaporated, freeze-dried, and spray-dried) were studied by 
SEM using JSM-5400 equipment, employing 20 kV of ten-
sion after sputtering the samples with a thin layer of gold to 
make the surfaces conductive.
In vivo assays
Animals
Experiments were carried out in male Wistar rats (280–
320 g) bred at the animal facility of the Biological Science 
Institute (CEBIO, Federal University of Minas Gerais, Belo 
Horizonte, Brazil). The animals had free access to food and 
water and were submitted to a light–dark cycle (12 hours 
each) before experiments. The experimental protocol was 
performed in accordance with the guidelines for the human 
use of laboratory animals of the cited institute and approved 
by local authorities.
Blood pressure recording in rats
Arterial pressure measurements
The cardiovascular parameters pulse arterial pressure (PAP), 
mean arterial pressure (MAP), and heart rate (HR) were 
monitored by a solid-state strain gauge transducer connected 
to a computer through a data acquisition system (MP 100; 
BIOPAC Systems, Inc, Goleta, CA). The PAP, MAP, and 
HR were monitored jointly during experiments in different 
monitor channels and recorded in the computer hard disk 
for posterior analysis.
Inhibition of the pressor effect  
of angiotensin I on BP in conscious  
Wistar rats
Twenty hours before the experiment, under tribromoethanol 
anesthesia (2.5% 1.0 mL 100 g−1 of body weight), polyeth-
ylene catheters (PE-10 connected to PE-50) were introduced 
into abdominal aorta through the femoral artery and vein for 
recording cardiovascular parameters and intravenous injec-
tions, respectively. After recovery from anesthesia, the rats 
were kept in individual cages with free access to water and 
food until the end of the experiments. Before drug admin-
istration, the cardiovascular parameters were monitored for 
10–15 minutes. Next, a continuous intravenous infusion of 
angiotensin I (30 ng 50 µL−1 min−1) was performed using 
an infusion pump (Pump 11; Harvard Apparatus, Holliston, 
MA). After stabilization of cardiovascular parameters dur-
ing angiotensin I infusion, CAP, CAP/CD complexes, or 
vehicle (water) were given by gavage (0.09 mg kg−1 and 
0.5 mg kg−1 of CAP in each formulation) in a total volume 
of 0.3 mL. Uncomplexed CAP was used as positive control. 
The cardiovascular parameters were monitored continuously 
over 2 hours after drug administration. MAP and HR values 
were computed at regular intervals (3 minutes, 15 minutes, 
30 minutes, 45   minutes, 60 minutes, 75 minutes, 90 minutes, 
105 minutes, and 120 minutes) (n = 4–7). Also, PAP, MAP, 
and HR parameters were monitored after 20–24 hours of 
administration.
statistical analysis
Comparisons were made by Student’s unpaired t-test or two-
way analysis of variance with Bonferroni post hoc test when 
appropriate. GraphPad Prism 5.0 software (GraphPad Soft-
ware, Inc, La Jolla, CA) was used in all statistical analysis. The 
criterion for statistical significance was set at P < 0.05.
Results and discussion
NMr
We initiated our investigation by analyzing the complexation-
induced chemical shifts (CICSs)20 in the complexes. The 
hydrogen atoms of guest molecules included in the CD 
nanocavities, as well as CD hydrogens, can undergo changes 
in chemical shifts due to the changes in their local environ-
ment. As has been frequently observed,21,22 the signals of H3’ 
and H5’ hydrogens on the inner surface of the CD (Figure 1) 
are shifted significantly upfield, whereas H1’, H2’, and H4’ 
hydrogens on the outer surface experience minimal changes. International Journal of Nanomedicine 2011:6
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Figure 2 1h nuclear magnetic resonance spectra showing α-cyclodextrin (α-cD, 
upper panel), captopril (cAP) (in the middle), and cAP/α-cD:kneading method 
(lower panel) in the 0.1–6.0 ppm range. A residual water signal is present at 4.8 ppm 
and evident in all samples.
Table 1 1h NMr chemical shifts of cyclodextrin (cD) hydrogens in D2O and their cIcs in the respective complexes, for α-cD 
(α-cyclodextrin) and its formulation with captopril (cAP/α-cD:KM); β-cD (β-cyclodextrin) and its formulation (cAP/β-cD:sD); hP-
β-cD (hydroxypropyl-β-cyclodextrin) and its formulation (cAP/hP-β-cD:sD)
H α-CD CAP/α-CD:KM β-CD CAP/β-CD:SD HP-β-CD CAP/HP-β-CD:SD
δ δ (Δδ) δ δ (Δδ) δ δ (Δδ)
1′ 5.08 5.08 (0) 5.10 5.09 (−0.01) 5.26 5.25 (−0.01)
2′ 3.66 3.67 (0.01) 3.68 3.67 (−0.01) 3.60 3.65 (0.05)
3′ 4.01 4.00 (−0.01) 3.99 3.96 (−0.03) 5.10 5.10 (0)
4′ 3.61 3.61 (0) 3.61 3.61 (0) 1.18 1.17 (−0.01)
5′ 3.90 3.88 (−0.02) 3.90 3.88 (−0.02) 3.94 3.91 (−0.03)
Note: Δδ = δcomplexed − δfree.
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Thus, the chemical displacement of the CDs induced by the 
presence of the guest and the CICSs of CAP are the first 
evidence of CAP inclusion in CDs (Figure 2).
The hydrogen atoms of CAP and the CDs were denomi-
nated in accordance with Figure 1, and the best results for 
formulations are summarized in Tables 1 and 2.
The chemical shifts of H6’ hydrogens (CDs) are not 
shown in Table 1 because of the overlap with the signals cor-
responding to H5’, which are also not shown. As is already 
described in the literature,23 when |Δδ Η3’|.|Δδ Η5’|, the 
guest inclusion inside the CD cavity is partial, and when 
|Δδ Η3’|#|Δδ Η5’|, the guest is included more deeply into 
the cavity. The results (Table 1) showed partial inclusion of 
CAP in β-CD nanoparticles and total inclusion of CAP in 
α-CD and HP-β-CD.
Unfortunately, the H5 CAP hydrogens (proline ring) of 
CAP could not be quantitatively analyzed due to overlapping 
with the NMR signals from the CD.
Table 2 shows the chemical shifts of the CAP hydrogens 
and their CICSs due to complexation with CDs. The CICS 
of CAP complexed with α-CD are higher than those mea-
sured in β-CD and HP-β-CD complexes, maybe because of 
stronger guest interactions with the α-CD cavity. In the case 
of the α-CD complexes, higher CICSs were observed for the 
propyl thioalcohol hydrogen (H9a) when compared with the 
proline hydrogens (H2 and H3). The CICSs of the β-CD and 
β-HP-CD follow a slightly different tendency. The larger 
ones were observed for hydrogens in the center of the CAP 
molecule (H7 and H8), whereas the changes in CICSs of 
the terminal hydrogens (H9) were small. These results sug-
gest that the terminal alkyl unit (thiol moiety) of the CAP 
is included in the CD cavity. The CICS data confirmed our 
expectations that CAP in an inclusion complex with α-CD in 
the formulation denominated CAP/α-CD:KM presents higher 
values, due to having stronger intramolecular interactions 
with the host molecule, as well as CAP insertion with the thiol 
moiety in the α-CD cavity, which is also observed in FTIR 
analysis. Other CAP inclusion complexes with β-CD and 
HP-β-CD collaborated with FTIR data and indicated more 
probable guest molecule inclusion by the proline moiety in 
the corresponding CD cavities.
rOesY NMr
The ROESY experiments were carried out in order to gain 
insights into the inclusion mode of the complexes in aqueous 
solution. The ROESY spectrum, shown in Figure 3, provided 
information about which α-CD hydrogen has an intermo-
lecular correlation with the CAP hydrogens. There are ROE 
crosspeaks between the H-4 and the α-CD H-6’ hydrogen 
resonances (in purple in Figure 3), as well as H-8 and H-3’ 
(in red in Figure 3). Additionally, we can find another ROE 
crosspeak between the H-9 and H-5’ hydrogen resonances International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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Figure 3 rotating-frame Overhauser enhancement spectroscopy nuclear magnetic resonance map (0.3–6.0 ppm range) with interactions between hydrogen atoms in the 
formulation captopril (cAP)/α-cyclodextrin (cD):kneading method. cAP h-9 and α-cD h-5’ (in green), h-4 and h-6’ (in purple), and h-8 and h-3’ (in red). residual water 
signal is present at 4.8 ppm. The α-cD (lower panel) and cAP (upper panel) are shown on the left side.
Table 2 1h NMr chemical shifts of captopril hydrogens in D2O 
and their cIcs in the complexes with α, β and hP cyclodextrins 
respectively, where Δδ = δcomplexed − δfree
Captopril CAP/α-CD: 
KM
CAP/β-CD: 
SD
CAP/HP-β-CD: 
SD
δ δ (Δδ) δ (Δδ) δ (Δδ)
2 4.48 4.54 (0.06) 4.50 (0.02) 4.49 (0.01)
5 3.82 – – –
5 3.73 – – –
7 3.02 3.01 (-0.01) 2.95 (-0.07) 2.98 (-0.04)
9a 2.70 2.82 (0.12) 2.72 (0.02) 2.72 (0.02)
9b 2.63 2.66 (0.03) 2.63 (0) 2.64 (0.01)
3 2.35 2.39 (0.04) 2.35 (0) 2.34 (-0.01)
4 2.06 2.08 (0.02) 2.10 (0.04) 2.09 (0.03)
8 1.17 1.25 (0.08) 1.22 (0.05) 1.21 (0.04)
(circled in green in Figure 3) that confirms the inclusion 
mode for the complex CAP/α-CD:KM in aqueous solution 
obtained by CICS analysis.
DOsY NMr
The DOSY NMR experiments were important to confirm 
the complexation of CAP with CD, and the diffusion 
coefficients also provided valuable information on molecu-
lar organization and phase structures. These experiments 
allowed distinguishing complexes by observed differences 
in diffusion coefficients. Furthermore, we have investigated 
the self-assemblies between host and guest molecules by 
mixing solutions of CAP and the respective CD (D2O) in the 
same proportion as used in the preparation of nanoparticles 
(1:1 molar ratios). As explained in the experimental section, 
after properly preprocessing data, the diffusion coefficients 
were obtained automatically and the diffusion coefficient 
values were calculated as the averages of all the listed coef-
ficients. The results for the best IC are shown in Table 3.
The guest population involved in the complexation 
was calculated from the observed diffusion coefficient of 
each component in the complexed and free forms, apply-
ing a well-established methodology.24,25 The degree of 
complexation between CAP and α-CD is evidently higher 
compared with other samples and occurred even in the self-
assembled sample (Table 3, mixture of α-CD + CAP, 23.6%); 
therefore, it was proven that CAP is completely included 
in the α-CD cavity, as already seen in the 1H NMR data. 
A somewhat higher degree of complexation was measured International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Table 3 Diffusion coefficients (D) obtained in DOSY-NMR experiments for Captopril (free and bonded) and cyclodextrins (α, β and 
hP-β-cD) with corresponding percent of captopril complexed population (pcomplexed in %)
Solution Dcaptopril/10-10 m2s-1 DCD/10-10 m2s-1 Pcomplexed (%)
free captopril 4.26 ± 0.02 – –
free α-cD – 2.33 ± 0.01 –
cAP/α-cD:KM 3.59 ± 0.07 2.30 ± 0.01 34.2
Mixture α-cD + captopril 3.78 ± 0.05 2.23 ± 0.04 23.6
free β-cD – 2.28 ± 0.01 –
cAP/β-cD:sD 3.6 ± 0.1 2.15 ± 0.01 31.3
Mixture β-cD + captopril 4.17 ± 0.04 2.21 ± 0.05 4.4
free hP-β-cD – 1.95 ± 0.02 –
cAP/hP-β-cD:sD 3.8 ± 0.3 1.95 ± 0.04 20.0
Mixture hP−β-cD + captopril 4.29 ± 0.08 2.04 ± 0.06 1.4
for CAP/α-CD:KM formulation (34.2%), as well as for 
CAP/β-CD:SD (31.3%).
NMR data enabled the pattern for supramolecular inter-
actions to be established and to propose the model for a 
host-guest complex named CAP/α-CD:KM, as illustrated 
in Figure 4.
13c-NMr and 2D NMr
13C-NMR and HSQC experiments were executed to confirm 
the results obtained by the  1H-NMR and ROESY experi-
ments and helped to better understand the supramolecular 
interactions between CAP and the CD. The 13C chemical shift 
displacements of α-CD and CAP in the formulations follow 
the same tendency observed in the 1H CICS, with greater 
displacements in C7, C8, and C9 of CAP. Furthermore, the 
{13C-1H} HSQC experiment helped us to clear up doubts in 
guest-host interactions that showed that proline moiety is the 
most altered in complex with α-CD, and the C7-H7, C8-H8, 
and C9-H9 correlation signals suffered significant shifts in 
comparison with the HSQC map of CAP.
FTIr spectroscopy
All solids were analyzed by FTIR, but this technique was only 
effective in analyzing the binary systems obtained by spray-
drying in the case of β-CD inclusion complexes, and by the 
kneading method in the case of α-CD inclusion complexes. 
The general trend of spectra showed that CAP IR bands are 
masked by CD IR bands (data not shown). When analyzing 
the IR spectra of CAP/β-CD:SD and CAP/α-CD:KM, it 
appeared that the CAP IR band attributed to axial strain S-H 
(2565 cm-1) disappeared when compared with the IR spectra 
of compounds obtained by other methods. Also, aliphatic C-H 
stretching and C-N IR bands in the 2800–3000 cm-1 region 
were missing. Therefore, the β- and α-CD probably interacted 
with CAP thiol and proline moieties by completely accom-
modating the guest within the corresponding nanocavity. 
These inclusion complexes in both control and preclinical 
tests were the ones with the best performance in maintaining 
stable blood pressure upon angiotensin I infusion.
Dsc
Data indicated that CAP has a thermal curve typical for a crys-
talline anhydrous substance with a sharp fusion endotherm at 
103–108°C, corresponding to the melting point of the drug. The 
DSC curve obtained for β-CD had a broad endothermic effect 
around 85–90°C, associated to crystal water losses from CD.26 
When physical mixtures were analyzed by DSC (Figure 5), 
the CAP endothermic peak around 103–108°C was clearly 
distinguishable from additional peaks, due to the β-CD dehy-
dration effect. These curves are, in fact, the superposition of the 
individual DSC components curves,27 showing the absence of 
interaction between the drug and CD in such systems.
It is known that when guest molecules are embedded in 
CD cavities or in the crystal lattice, their melting, boiling, 
or sublimation points generally shift to a different tem-
perature or disappear within the temperature range where 
A B
Figure 4 Proposed structure for captopril and α-cyclodextrin (cD) in the captopril 
(cAP)/α-cD:kneading method inclusion complex. The cAP is completely included 
in the α-cD cavity; α-cD upper and broader cone side accommodates cAP whose 
thiol moiety is completely introduced into the cavity and is illustrated in two different 
perspectives (A) and (B). The hydrogen atoms in green (h-9), purple (h-4), and red 
(h-8) on the cAP molecule are the most altered by complexation, as measured in 
rotating-frame Overhauser enhancement spectroscopy nuclear magnetic resonance 
and seen by complexation-induced chemical shifts.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Figure 5 Differential scanning calorimetry thermograms of A) captopril (cAP), B) β-cyclodextrin (cD), C) cAP/β-cD:physical mixture, and D) cAP/β-cD:spray-dried.
CD is decomposed.28 Therefore, the disappearance of the 
CAP melting point in the CAP/α-CD:SD, CAP/α-CD:KM, 
and CAP/HP-β-CD:SD inclusion complexes suggests the 
formation of amorphous solid dispersion and/or inclusion 
complexes.29 These results provide strong evidence that only 
four nanoparticles, CAP/α-CD:SD, CAP/α-CD:KM, CAP/
HP-β-CD:SD, and CAP/β-CD:VE, can be considered true 
inclusion complexes.30
XrD studies
The XRD patterns of CAP/β-CD, CAP/α-CD, and CAP/
HP-β-CD systems are presented in Figure 6. CAP, α-CD, International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Figure  6  X-ray  powder  diffraction  of  A)  captopril  (cAP),  B)  α-cyclodextrin 
(cD), C) β-cD, D) cAP/α-cD:physical mixture, E) cAP/β-cD:PM, F) cAP/α-
cD:kneading method, and G) cAP/β-cD:spray-dried.
Figure 7 scanning electron microscopy images of A) captopril (cAP)/α-cyclodextrin 
(cD):physical  mixture,  B)  cAP/β-cD:physical  mixture,  C)  cAP/α-cD:kneading 
method, and (D) cAP/β-cD:spray-dried.
A B
C D
Figure 7 scanning electron microscopy images of A) captopril (cAP)/α-cyclodextrin 
(cD):physical  mixture,  B)  cAP/β-cD:physical  mixture,  C)  cAP/α-cD:kneading 
method, and (D) cAP/β-cD:spray-dried.
and β-CD exhibited intense peaks and crystalline struc-
ture   (Figure 6A–C). The XRD pattern of CAP/β-CD:PM 
 ( Figure 6E) is practically constituted from the superposition 
of the spectra corresponding to the individual components, 
providing evidence that an inclusion complex was not 
formed. The reduction in crystallinity was complete in the 
spray-dried powder (CAP/β-CD:SD, Figure 6G), showing 
a completely diffuse diffraction pattern, which revealed its 
amorphousness.
The absence of any peak in the HP-β-CD diffractograms 
revealed the amorphous nature of this compound (data not 
shown). The other HP-β-CD systems displayed diffuse dif-
fraction patterns (identical to those of HP-β-CD without 
drug peaks), indicating the entirely amorphous nature of 
CAP in these products. As for α-CD, the diffraction profile 
of the CAP/α-CD:PM sample was found to be the simple 
superposition of XRD of each component (Figure 6D). The 
reduction in crystallinity was evident in the kneaded powder 
(CAP/α-CD:KM, Figure 6F), with the crystalline peaks of 
CAP emerging in the diffuse background. These results may 
be attributed to an interaction between CAP and α-CD and 
β-CD, in the kneaded and spray-dried products, suggesting 
the presence of a new solid phase with lower crystallin-
ity than the drug, where a possible complexation of CAP 
inside the CD cavity was contemplated, corroborating the 
DSC observations.
seM studies
Although the SEM technique is not suitable to prove the 
formation of an inclusion complex, it can confirm the exis-
tence of one or several components and supply information 
about particle size and shape. SEM studies revealed that CD 
crystallizes in polyhedral form. Pure CAP examined by SEM 
appeared as crystal particles with large dimensions, and its 
physical mixtures with α- and β-CD showed both crystalline 
components (Figures 7A and 7B).
Microphotographs of the samples prepared by kneading 
and spray-drying for α- and β-CD showed a strong reduction 
in the particle size (Figures 7C and 7D) due to the processing 
methods employed, which provoked a high degree of particle 
agglomeration, although the wetability of CAP increased. 
The vacuum-evaporated samples show clear differences in 
crystallization, with new crystalline products in CAP inclu-
sion complexes with both CDs (data not shown).International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Figure 8 reduction of the angiotensin I pressor response in conscious rats provoked with administration of two captopril (cAP) inclusion complexes at a dose of 
A) 0.5 mg kg−1 (cAP concentration in each inclusion complex) and B) 0.09 mg kg−1. Both graphics show cAP-free effects. complexes of α- and β-cyclodextrin showed long-
lasting inhibitory effects when compared with cAP (P , 0.05).
Table 4 Maximum percent changes in MAP following captopril 
and captopril/cyclodextrin complexes (0.09 and 0.5 mg kg−1 of 
captopril in each complex) administration
Inclusion  
complex
0.09 mg (CAP) kg-1 0.5 mg (CAP) kg-1
% Time  
(min)
% Time   
(min)
cAP/β-cD:sD 71 ± 7* 30 75 ± 2 30
cAP/β-cD:FD 67 ± 14 30 60 ± 14 45
cAP/β-cD:Ve 58 ± 5 15 65 ± 15 45
cAP/β-cD:KM 67 ± 8 45 80 ± 6 60
cAP/α-cD:KM 80 ± 9* 30 87 ± 6* 60
cAP/α-cD:sD 66 ± 12 45 78 ± 7 60
captopril 53 ± 8 15 66 ± 10 30
Note: *P , 0.05 when compared to captopril. Data presented as mean ± sD.
In vivo evaluation
Blood pressure recording in rats
The results showed that all investigated inclusion com-
plexes as well as CAP reduced the pressor response 
evoked by angiotensin I. Figure 8 shows the inhibitory 
effects of two CAP/CD complexes (0.5 mg kg−1 CAP in 
each inclusion   complex, or 0.09 mg kg−1 CAP) on the 
pressor response caused by the infusion of angiotensin I 
on the MAP of conscious rats in comparison with CAP-
free infusions.
Complexes of CAP with α- and β-CD showed a 
long-lasting inhibitory effect when compared with CAP 
(P < 0.05). The inclusion complex CAP/β-CD:SD (illus-
trated in red) presented a similar time course to that of 
CAP, evoking a maximum inhibitory effect at 30 minutes. 
This inhibitory effect was still evident until the end of the 
experimental period (120 minutes showed).
Table 4 shows the maximum percent changes of the 
angiotensin I pressor effect for the various investigated CAP 
formulations. These values were collected at the time when 
maximum reductions in MAP were observed after inclusion 
complex or CAP administration (0.09 and 0.5 mg kg−1 of 
CAP in each case). At both doses, CAP/α-CD:KM was the 
most potent inhibitor of the pressor effect of   angiotensin I. 
Also, the inhibitory effect of CAP/α-CD:KM was signifi-
cantly different from that of CAP (P , 0.05).
Three complexes, CAP/β-CD:SD, CAP/β-CD:VE, and 
CAP/α-CD:KM, evoked a maximum response at 15   minutes, 
45 minutes, and 60 minutes, respectively. A reduction of 
this effect was observed at 90 minutes, 75 minutes, and 
105 minutes, respectively (data not shown). CAP caused 
maximum inhibitory response at 30 minutes after injection, 
showing a reduction of its inhibitory effect 75 minutes after 
administration. Although all investigated complexes showed 
longer-lasting inhibitory effects when compared with CAP 
(P < 0.05), two formulations, CAP/α-CD:KM and CAP/β-
CD:SD, exhibited the best results. The CAP/β-CD:SD (red, 
Figure 8A) and CAP/α-CD:KM (blue, Figure 8A) com-
plexes evoked a maximum inhibitory effect on the pressor 
response evoked by angiotensin I at 30 minutes. However, 
a decay of this effect was observed from 60 minutes to 
90 minutes for CAP/β-CD:SD (red, Figure 8A). The maxi-
mum response of the complex CAP/α-CD:KM started at 
30 minutes following its administration, showing a stable 
inhibitory effect up to the end of the observation period 
(blue, Figure 8A). Moreover, this effect was detected even 
22 hours after CAP/α-CD:KM administration, indicating 
a very long-lasting pressor effect on angiotensin I, as if 
CAP in this formulation was protected from degradation International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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and liberated in portions during MAP monitoring. In all 
experiments, free CAP showed a maximum inhibitory 
response at 30 minutes after injection. A gradual reduc-
tion of its inhibitory effect was observed 45 minutes after 
administration (Figure 8B).
Therefore, the in vivo results showed relevant infor-
mation about the activity of CAP and the CD inclusion 
complexes. Moreover, the methodology used in our study 
allowed the   evaluation of the effectiveness of different 
inclusion   complexes. Two of them, CAP/α-CD:KM and 
CAP/β-CD:SD, showed potent and long-lasting inhibitory 
activity over the pressor response of angiotensin I. These two 
compounds should be further evaluated in chronic studies 
aimed at clinical applications.
Final remarks
In this report, we have provided detailed physicochemical 
characterization of inclusion compounds formed through 
different procedures between CAP and three different 
CDs, and showed that the kneading method resulted in the 
best inclusion organization for the CAP/α-CD:KM nano-
particles. This formulation showed the highest degree of 
complexation (superior to 34%), and then data collected 
enabled us to propose a solid model for the inclusion 
complexes that describes all supramolecular interactions 
acting between CAP and α-CD. NMR data, such as ROESY 
and DOSY, were very informative and indicated that even 
hydrophilic species such as CAP are involved in CD cavi-
ties in water solution, including self-assembly. Although 
self-assemblies between CD and CAP gave good complex-
ation results, two inclusion complex formulations seem to 
additionally complex CAP and explain in vivo bioactivity 
data. Two formulations exhibited long-lasting effects in 
controlling angiotensin I pressor effect, especially the inclu-
sion complexes CAP/α-CD:KM formulation. Therefore, 
this could be a new way for CAP administration that may 
provide better quality of life for people suffering from high 
blood pressure, who compose around 25% of the world’s 
population.
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